← All trials
NCT04701151
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 3, 2021
- Primary completion
- Feb 28, 2022
- Completion date
- Nov 30, 2023
- First posted
- Jan 8, 2021
- Last posted
- Feb 5, 2021
- Enrollment
- 314
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Aarhus UniversityLead sponsor
- Aarhus UniversitySponsor investigator
- Aarhus UniversityCollaborator
- University of CopenhagenCollaborator
- University of GothenburgCollaborator
- University of Southern DenmarkCollaborator
- University of IcelandCollaborator
- University of CopenhagenCollaborator
- Orebro UniversityCollaborator
- University of CopenhagenCollaborator
- The Hospital of VestfoldCollaborator
- Regional Hospital West JutlandCollaborator
- Aalborg UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.